ArticleEJVES vascular forum2026
International Cross Sectional Survey on the Management of Visceral Artery Aneurysms and Isolated Dissections from the European Visceral Artery Revascularisation (EVisAR) Study Participants.
Article in EJVES vascular forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06913530 (European Multicentre Study of Long-term Results Following Visceral Arteries Revascularization), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
European Multicentre Study of Long-term Results Following Visceral Arteries Revascularization: the E-VisAR Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Visceral artery aneurysms (VAAs) and isolated mesenteric and renal artery dissections (IMAD and IRAD) are uncommon conditions with unclear natural histories and uncertainties due to the lack of level 1 evidence guiding optimal management. This study was part of the European Visceral Artery Revascularisation (EVisAR; ClinicalTrial.gov NCT06913530) study initiative. A single round, international, cross sectional online survey, in compliance with the Checklist for Reporting of Survey Studies (CROSS), was conducted to assess current heterogeneity for the management of VAAs, IMAD, and IRAD across Europe. Method: EVisAR physicians were invited and surveyed with questions on caseload, diagnostic pathways, treatment indications and strategies, and follow up protocols. Responses were analysed descriptively, and inter-physician agreement was estimated with the Fleiss κ method. Results: A total of 54 physicians completed the survey (of 107 invited); 98% were vascular surgeons from 12 European countries and one from Australia. Institutional caseloads were low (fewer than ten cases/year) for both conditions. Aneurysm size thresholds for intervention varied depending on the location, with 2 - 3 cm being common for several arteries and an agreement for a 3 cm threshold for renal and splenic artery aneurysms (74% and 65%, respectively). Endovascular intervention was the preferred approach for VAAs and dissections (98%). Initial IMAD management largely depended on clinical status and most frequently included triple medication (antihypertensive, anticoagulant, and antiplatelet, 68%), fasting (63%), monitoring of biomarkers for intestinal ischaemia (89%), and a second scan at one to three days (63%). Overall agreement on management was moderate for VAA (κ = 0 .41) and IMAD and IRAD (κ = 0.40). For both, the lowest agreement was observed for follow up indications (κ = 0.03 and κ = 0.32, respectively). Conclusions: Current management shows substantial heterogeneity and a lack of consensus, particularly concerning long term surveillance and specific therapeutic approaches, although endovascular interventions seem to be the preferred strategy. These findings underscore the urgent need for high quality data and support the ongoing need for the EVisAR study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.